Franz Thomas Walt

Franz Thomas Walt (*1959, Switzerland) holds an MBA of City University, Bellevue, Washington and completed executive programs at Columbia University, IMD, Switzerland, London Business School and INSEAD, France.

Following his studies, Mr. Walt spent over 30 years in leadership roles at two of the world’s largest healthcare companies, Roche and Siemens Healthineers. Between 1989 and 2011 he held various positions of increasing responsibility in pharmaceuticals and diagnostics, including the roles of CEO, Managing Director, and President, in various geographic regions for Roche Diagnostics. He also served for eight years as a member of the global Roche Diagnostics Executive Committee (DiaEC). Between 2012 and 2017, he worked for Siemens Healthineers AG, most recently as global President of Laboratory Diagnostics. From 2018 to 2021, Mr. Walt was CEO of NASDAQ-listed Quotient Ltd. based in Eysins, Switzerland.

Mr. Walt has been a member of the Supervisory Board of Epigenomics AG since May 2019. He is an independent member (within the meaning of the German Corporate Governance Code). Mr. Walt’s current appointment ends in 2024.

Mr. Walt is not a member of other mandatory supervisory boards.

He is a member of comparable control committees of the following companies: amedes Holding GmbH, Hamburg, Germany, and Aragon Holding JV S. a r. l., Luxembourg.